Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., X is oxygen, etc., Y is carbon, etc., Z is C1-6 alkyl, etc., m and n are an integer of 0, 1, 2, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

Abstract: The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

Abstract: A solidification position measuring apparatus for measuring a solidification position of a cast-piece includes: an electromagnetic acoustic transducer installed outside the cast-piece; a sensor lifting and lowering unit configured to adjust a gap between the cast-piece and the electromagnetic acoustic transducer; a gap measuring unit configured to measure the gap between the cast-piece and the electromagnetic acoustic transducer; a computing unit configured to estimate the solidification position in the cast-piece from an output of the electromagnetic acoustic transducer; and a drive control unit configured to drive and control the sensor lifting and lowering unit and the gap measuring unit. The drive control unit is configured to control a position of the electromagnetic ultrasonic sensor by the sensor lifting and lowering unit based on the gap measured by the gap measuring unit.

Abstract: The present disclosure provides a method for recovering an ionic liquid from a mixed liquid containing the ionic liquid and an organic acid.

Abstract: The present disclosure provides a method for recovering an ionic liquid from a liquid mixture containing the ionic liquid and an organic acid.

Abstract: A transplantation medium for subretinal transplantation of a retinal pigment epithelial cell contains hyaluronic acid and a pharmaceutically acceptable aqueous liquid, in which the viscosity of the transplantation medium at a shear rate of 2 (1/s) at 25° C. is 1.5 to 4 mPa·s.

Abstract: A motion-detection method includes for a motion-detection region in a first image of a scene, (i) determining a respective first pixel-value gradient at each of a plurality of pixel-coordinates within the motion-detection region, and (ii) determining a first feature-descriptor value as a function of the first pixel-value gradients and position vectors defined by the plurality of pixel-coordinates. The method also includes, for the motion-detection region in a second image of the scene, (i) determining a respective second pixel-value gradient at each of the plurality of pixel-coordinates, and (ii) determining a second feature-descriptor value as a function of the second pixel-value gradients and the position vectors. The method also includes determining a difference-parameter that varies in direct relationship to a difference between the first feature-descriptor value and the second feature-descriptor value.

Abstract: The present invention provides a fused-ring amine derivative that has a DYRK inhibitory effect and that is represented by formula (1) (refer to the description with respect to A1, L1, T, Z and l in the formula), or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

Abstract: The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: A faceplate that is attached to a circuit board on the side of an extraction direction in which the circuit board is extracted from a slot includes: a main body that covers an opening of the slot; and two handle portions that are disposed respectively at both ends of the main body with respect to a width direction of the circuit board and that extend in the extraction direction. The two handle portions have respective distal ends shifted from each other in a thickness direction of the circuit board. Multiple slots are formed in a casing of an electronic device along a width direction thereof.

Abstract: A particle size distribution measurement device includes a cell holding body 31 that holds a measurement cell 2 containing a measurement sample and a dispersion medium and a reference cell 6 containing a reference sample and is rotated by a motor 322, and a cell discrimination mechanism 7 that discriminates the cells 2, 6 passing through a predetermined rotation position by using a magnetic force or electrostatic capacitance.

Abstract: The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: An ID management unit allocates a first connection ID to a first vehicle in a first period and allocates the first connection ID to a second vehicle in a second period. A correction information acquisition unit connects to a distribution device using the first connection ID and receives correction information for the first vehicle from the distribution device in the first period. The correction information acquisition unit connects to the distribution device using the first connection ID and receives the correction information for the second vehicle from the distribution device in the second period. With the system, it is possible to reduce waste of connection IDs necessary for connection to the distribution device that distributes correction information for realizing high-accuracy positioning.